NASDAQ:COLL - Collegium Pharmaceutical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $18.14 -0.57 (-3.05 %) (As of 12/16/2018 04:00 PM ET)Previous Close$18.14Today's Range$18.04 - $19.0252-Week Range$13.70 - $29.90Volume365,640 shsAverage Volume408,293 shsMarket Capitalization$603.10 millionP/E Ratio-7.34Dividend YieldN/ABeta0.29 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. Receive COLL News and Ratings via Email Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:COLL Previous Symbol CUSIPN/A Webwww.collegiumpharma.com Phone781-713-3699 Debt Debt-to-Equity Ratio4.17 Current Ratio0.78 Quick Ratio0.75 Price-To-Earnings Trailing P/E Ratio-7.34 Forward P/E Ratio-9.97 P/E GrowthN/A Sales & Book Value Annual Sales$28.48 million Price / Sales21.18 Cash FlowN/A Price / Cash FlowN/A Book Value$3.20 per share Price / Book5.67 Profitability EPS (Most Recent Fiscal Year)($2.47) Net Income$-74,860,000.00 Net Margins-30.13% Return on Equity-70.06% Return on Assets-11.34% Miscellaneous Employees250 Outstanding Shares33,250,000Market Cap$603.10 million OptionableOptionable Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions What is Collegium Pharmaceutical's stock symbol? Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL." How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical Inc (NASDAQ:COLL) released its quarterly earnings results on Thursday, November, 8th. The specialty pharmaceutical company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.14. The specialty pharmaceutical company had revenue of $70.20 million for the quarter, compared to analysts' expectations of $74.79 million. Collegium Pharmaceutical had a negative return on equity of 70.06% and a negative net margin of 30.13%. Collegium Pharmaceutical's revenue for the quarter was up 485.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.45) earnings per share. View Collegium Pharmaceutical's Earnings History. When is Collegium Pharmaceutical's next earnings date? Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for Collegium Pharmaceutical. What price target have analysts set for COLL? 7 equities research analysts have issued 1-year price objectives for Collegium Pharmaceutical's stock. Their predictions range from $27.00 to $35.00. On average, they expect Collegium Pharmaceutical's stock price to reach $32.6667 in the next twelve months. This suggests a possible upside of 80.1% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical. What is the consensus analysts' recommendation for Collegium Pharmaceutical? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical. What are Wall Street analysts saying about Collegium Pharmaceutical stock? Here are some recent quotes from research analysts about Collegium Pharmaceutical stock: 1. According to Zacks Investment Research, "Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. " (11/9/2018) 2. Cantor Fitzgerald analysts commented, ". Post 3Q18, we are reiterating our Overweight rating and our 12-month price target of $35. We remain positive on the long-term growth potential of Xtampza, which we expect to be the leading branded extended-release oxycodone over time. We think the company is only in the early stages of building a much-larger portfolio of differentiated opioid and non-opioid pain treatments. Collegium has shown a willingness to work with payers to ensure that the company’s products are available to patients without excessive payer restrictions. Collegium’s lead growth driver is Xtampza, which we continue to believe will replace OxyContin as the largest branded oxycodone ER product." (11/8/2018) Has Collegium Pharmaceutical been receiving favorable news coverage? Media stories about COLL stock have trended somewhat positive on Sunday, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Collegium Pharmaceutical earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. Who are some of Collegium Pharmaceutical's key competitors? Some companies that are related to Collegium Pharmaceutical include Ultragenyx Pharmaceutical (RARE), Endo International (ENDP), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Myokardia (MYOK), Xencor (XNCR), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), Endocyte (ECYT), Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), Pacira Pharmaceuticals (PCRX), Corcept Therapeutics (CORT), Opko Health (OPK) and AnaptysBio (ANAB). Who are Collegium Pharmaceutical's key executives? Collegium Pharmaceutical's management team includes the folowing people: Mr. Michael T. Heffernan, Co-Founder & Chairman (Age 54)Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 47)Mr. Paul J. Brannelly, Exec. VP & CFO (Age 45)Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 43)Ms. Alex Dasalla, Head of Investor Relations When did Collegium Pharmaceutical IPO? (COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (12.40%), Macquarie Group Ltd. (7.63%), BlackRock Inc. (7.25%), Franklin Resources Inc. (5.29%), Vanguard Group Inc. (4.14%) and Vanguard Group Inc (4.14%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, Joseph Ciaffoni, Longitude Capital Partners, Ll, Michael Thomas Heffernan and Paul Brannelly. View Institutional Ownership Trends for Collegium Pharmaceutical. Which institutional investors are selling Collegium Pharmaceutical stock? COLL stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, FMR LLC, Macquarie Group Ltd., Bank of New York Mellon Corp, Fisher Asset Management LLC, Teton Advisors Inc., Credit Suisse AG and TIAA CREF Investment Management LLC. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, Joseph Ciaffoni, Michael Thomas Heffernan and Paul Brannelly. View Insider Buying and Selling for Collegium Pharmaceutical. Which institutional investors are buying Collegium Pharmaceutical stock? COLL stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Janus Henderson Group PLC, Massachusetts Financial Services Co. MA, Morgan Stanley, C WorldWide Group Holding A S, BlackRock Inc., Prudential Financial Inc. and Rice Hall James & Associates LLC. View Insider Buying and Selling for Collegium Pharmaceutical. How do I buy shares of Collegium Pharmaceutical? Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Collegium Pharmaceutical's stock price today? One share of COLL stock can currently be purchased for approximately $18.14. How big of a company is Collegium Pharmaceutical? Collegium Pharmaceutical has a market capitalization of $603.10 million and generates $28.48 million in revenue each year. The specialty pharmaceutical company earns $-74,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Collegium Pharmaceutical employs 250 workers across the globe. What is Collegium Pharmaceutical's official website? The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com. How can I contact Collegium Pharmaceutical? Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699. MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 241 (Vote Outperform)Underperform Votes: 249 (Vote Underperform)Total Votes: 490MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe COLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/16/2018 by MarketBeat.com StaffFeatured Article: What are the reasons investors use put options?